Shares of NLS Pharmaceutics Ltd. (NASDAQ:NLSP – Get Free Report) were up 4.1% on Wednesday . The company traded as high as $0.13 and last traded at $0.13. Approximately 168,951 shares were traded during trading, a decline of 96% from the average daily volume of 4,633,281 shares. The stock had previously closed at $0.12.
NLS Pharmaceutics Stock Performance
The business has a 50 day moving average of $0.18 and a two-hundred day moving average of $0.19.
Institutional Trading of NLS Pharmaceutics
A hedge fund recently raised its stake in NLS Pharmaceutics stock. Armistice Capital LLC grew its stake in shares of NLS Pharmaceutics Ltd. (NASDAQ:NLSP – Free Report) by 6.4% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 2,311,000 shares of the company’s stock after purchasing an additional 139,000 shares during the period. Armistice Capital LLC owned about 19.62% of NLS Pharmaceutics worth $501,000 as of its most recent filing with the SEC.
About NLS Pharmaceutics
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).
Further Reading
- Five stocks we like better than NLS Pharmaceutics
- What is Short Interest? How to Use It
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- Options Trading – Understanding Strike Price
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for NLS Pharmaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NLS Pharmaceutics and related companies with MarketBeat.com's FREE daily email newsletter.